This is a preview of subscription content, log in via an institution to check access.
Notes
poly(adenosine diphosphate [ADP]-ribose) polymerase
Reference
Gonzalez R, et al. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecologic Oncology : 27 Aug 2020. Available from: URL: https://doi.org/10.1016/j.ygyno.2020.08.003.
Rights and permissions
About this article
Cite this article
Targeted PARP inhibitors in advanced ovarian cancer "higher care value". PharmacoEcon Outcomes News 861, 32 (2020). https://doi.org/10.1007/s40274-020-7114-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7114-9